| NCT06657144 | A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2025-04-01 | 2027-05 | 2027-05 |
| NCT06389526 | A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors | NOT_YET_RECRUITING | PHASE1 | 2025-02-15 | 2028-05-30 | 2028-05-30 |
| NCT06679985 | A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | RECRUITING | PHASE2 | 2024-12-20 | 2027-09 | 2027-09 |
| NCT06457503 | A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | RECRUITING | PHASE4 | 2024-11-01 | 2027-12 | 2027-12 |
| NCT05757492 | Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors | TERMINATED | PHASE1 | 2023-04-26 | 2024-07-31 | 2024-07-31 |
| NCT05635643 | Study of CHS-114 in Participants With Advanced Solid Tumors | RECRUITING | PHASE1 | 2022-12-15 | 2026-02 | 2026-02 |
| NCT05359861 | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-04-12 | 2025-09 | 2025-08 |
| NCT05177770 | Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | TERMINATED | PHASE2 | 2022-01-17 | 2023-04-05 | 2023-04-05 |
| NCT04374877 | Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-04-22 | 2026-08 | 2025-12 |
| NCT04336098 | Study of SRF617 in Patients With Advanced Solid Tumors | COMPLETED | PHASE1 | 2020-03-16 | 2023-08-25 | 2023-08-25 |
| NCT02650973 | Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta | COMPLETED | PHASE1 | 2016-02 | 2016-06 | 2016-06 |
| NCT02489227 | Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis | COMPLETED | PHASE3 | 2015-08 | 2017-03 | 2016-05-06 |
| NCT02486939 | A Long Term Safety Extension Study (CHS-0214-05) | COMPLETED | PHASE3 | 2015-07 | 2017-10 | 2017-09 |
| NCT02418104 | Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta® | COMPLETED | PHASE1 | 2015-05 | 2015-12 | 2015-12 |
| NCT02385851 | Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim) | COMPLETED | PHASE1 | 2015-02 | 2015-07 | 2015-07 |
| NCT02134210 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) | COMPLETED | PHASE3 | 2014-06-16 | 2016-05-12 | 2015-07-27 |
| NCT02115750 | Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA) | COMPLETED | PHASE3 | 2014-05 | 2016-05 | 2015-10 |